DK2451844T3 - Tlr3-bindingsmidler - Google Patents
Tlr3-bindingsmidler Download PDFInfo
- Publication number
- DK2451844T3 DK2451844T3 DK10734092.9T DK10734092T DK2451844T3 DK 2451844 T3 DK2451844 T3 DK 2451844T3 DK 10734092 T DK10734092 T DK 10734092T DK 2451844 T3 DK2451844 T3 DK 2451844T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- tlr3
- antibodies
- amino acid
- ser
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Virology (AREA)
- Transplantation (AREA)
Claims (15)
1. Monoklonalt antistof, der specifikt binder et humant TLR3-polypeptid, hvor antistoffet hæmmer signalering ved hjælp af TLR3-polypeptidet uden at blokere binding af en dsRNA-TLR3-ligand til TLR3-polypeptidet, hvor antistoffet binder specifikt til TLR3-polypeptidet under neutrale betingelser ved et pH på mellem 6,6 og 7,4 og under sure betingelser ved et pH på mellem 4,5 og 6,5 med en subnanomolær KD for dets bivalente bindingsaffinitet; hvor antistoffet konkurrerer om binding til et TLR3-polypeptid med et antistof, der er udvalgt fra gruppen, der består af: (a) et antistof med et VH- og VL-område ifølge henholdsvis SEQ ID NO: 34 og 35 og (b) et antistof med et VH- og VL-område ifølge henholdsvis SEQ ID NO: 2 og 3.
2. Antistof ifølge krav 1, hvor antistoffet binder specifikt til TLR3-polypeptidet under sure betingelser med en 100 pikomolær eller bedre KD for dets bivalente bindingsaffinitet.
3. Antistof ifølge krav 1 til 2, hvor antistoffet er udvalgt fra gruppen, der består af: (a) et antistof med (i) tung kæde-CDR 1, 2 og 3 (HCDR1, HCDR2, HCDR3)-aminosyresekvenserne ifølge henholdsvis SEQ ID NO: 4, 5 og 6 og (ii) let kæde-CDR 1, 2 og 3 (LCDR1, LCDR2, LCDR3) -aminosyresekvenserne ifølge henholdsvis SEQ ID NO: 7, 8 og 9; og (b) et antistof med (i) tung kæde-CDR 1, 2 og 3 (HCDR1, HCDR2, HCDR3)-aminosyresekvenserne ifølge henholdsvis SEQ ID NO: 36, 37 og 38 og (ii) let kæde-CDR 1, 2 og 3 (LCDR1, LCDR2, LCDR3) -aminosyresekvenserne ifølge henholdsvis SEQ ID NO: 39, 40 og 41.
4. Antistof ifølge krav 1 til 3, hvor antistoffet er et kimært, humant eller humaniseret antistof.
5. Antistof ifølge krav 4, hvor isotypen af antistoffet er et IgG4.
6. Antistof ifølge krav 1 til 5, hvor antistoffet omfatter et Fc-områder, der er modificeret til reducering af dets FcyR-binding.
7. Antistof ifølge krav 1 til 6, hvor antistoffet er et antistoffragment, der er udvalgt blandt Fab, Fab', Fab'-SH, F(ab')2/ Fv, diabodies, enkeltkædet antistoffragment eller et multispecifikt antistof, der omfatter mangfoldige forskellige antistoffragmenter.
8. Antistof ifølge krav 1 til 7, hvor antistoffet er konjugeret eller kovalent bundet til en toksisk del.
9. Antistof ifølge krav 1 til 8, hvor antistoffet er i stand til at blive internaliseret af en TLR3-udtrykkende celle.
10. Antistof ifølge krav 1 til 9, hvor antistoffet er konjugeret eller kovalent bundet til en påviselig del.
11. Antistof ifølge krav 1 til 10, hvor antistoffet er dannet ved immunisering af et non-humant dyr med et immunogen, der omfatter et TLR3-polypeptid.
12. Hybridom eller rekombinant værtscelle, der danner antistoffet ifølge krav 1 til 11.
13. Farmaceutisk præparat, der omfatter et antistof ifølge et hvilket som helst af kravene 1-11 og et farmaceutisk acceptabelt bæremateriale.
14. Farmaceutisk præparat ifølge krav 13 til anvendelse til behandling eller forebyggelse af en sygdom, der er udvalgt fra gruppen, der består af autoimmunitet, inflammation, allergi, astma, infektion, cirrose og sepsis.
15. Farmaceutisk præparat ifølge krav 13 til anvendelse til behandling eller forebyggelse af en cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22454809P | 2009-07-10 | 2009-07-10 | |
PCT/EP2010/059946 WO2011004028A2 (en) | 2009-07-10 | 2010-07-09 | Tlr3 binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2451844T3 true DK2451844T3 (da) | 2015-07-27 |
Family
ID=42727505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10734092.9T DK2451844T3 (da) | 2009-07-10 | 2010-07-09 | Tlr3-bindingsmidler |
Country Status (10)
Country | Link |
---|---|
US (2) | US9388246B2 (da) |
EP (1) | EP2451844B1 (da) |
JP (1) | JP5800809B2 (da) |
CN (1) | CN102471382A (da) |
AU (1) | AU2010270163B2 (da) |
CA (1) | CA2766747C (da) |
DK (1) | DK2451844T3 (da) |
ES (1) | ES2543095T3 (da) |
RU (1) | RU2562865C2 (da) |
WO (1) | WO2011004028A2 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2350304T (lt) * | 2008-10-31 | 2017-02-10 | Janssen Biotech, Inc. | Toll tipo receptoriaus 3 antagonistai |
US8460659B2 (en) | 2008-10-31 | 2013-06-11 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases |
NZ592432A (en) | 2008-11-03 | 2013-01-25 | Alethia Biotherapeutics Inc | Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1) |
CA2766747C (en) | 2009-07-10 | 2019-04-02 | Innate Pharma | Tlr3 binding agents |
US20140065154A1 (en) * | 2011-01-12 | 2014-03-06 | Innate Pharma | Tlr3 binding agents |
ES2615387T3 (es) | 2011-03-31 | 2017-06-06 | Alethia Biotherapeutics Inc. | Anticuerpos contra el antígeno 1 asociado al riñón y fragmentos de unión al antígeno de estos |
WO2013078223A1 (en) * | 2011-11-23 | 2013-05-30 | Children's Hospital & Research Center Oakland | Anti-factor h binding protein antibodies and methods of use thereof |
CA2857400A1 (en) | 2012-01-09 | 2013-07-18 | Alethia Biotherapeutics Inc. | Anti-kaag1 antibodies or antigen binding fragment thereof for treatment of triple negative breast cancer |
ES2641444T3 (es) * | 2012-05-09 | 2017-11-10 | Eli Lilly And Company | Procedimiento de preparación de cloruros de 4-[[(benzoil)amino]sulfonil]benzoílo y preparación de acilsulfamoilbenzamidas |
DK2855527T3 (da) * | 2012-05-31 | 2018-11-26 | Innate Pharma | Tlr3-bindemidler |
EP3933406A3 (en) * | 2012-08-21 | 2022-04-20 | Janssen Pharmaceutica NV | Antibodies to risperidone and use thereof |
WO2015084262A2 (en) * | 2013-12-03 | 2015-06-11 | Agency For Science, Technology And Research | Cytotoxic antibody |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
KR20230172625A (ko) * | 2014-08-28 | 2023-12-22 | 바이오아트라, 인코퍼레이티드 | 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체 |
AU2017263568B2 (en) | 2016-05-13 | 2024-01-18 | Bioatla, Llc | Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EP4090681A1 (en) * | 2020-01-17 | 2022-11-23 | Biolegend, Inc. | Anti-tlr7 agents and compositions and methods for making and using the same |
WO2021207152A1 (en) * | 2020-04-06 | 2021-10-14 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
JP2024512305A (ja) * | 2021-03-03 | 2024-03-19 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 破骨細胞生成の新規制御因子としてのLaタンパク質 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US5491084A (en) | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
AR006928A1 (es) | 1996-05-01 | 1999-09-29 | Pioneer Hi Bred Int | Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas. |
KR100388860B1 (ko) | 1997-05-07 | 2003-06-25 | 쉐링 코포레이션 | 사람의 Toll-유사 수용체 단백질, 관련 시약 및 방법 |
ES2190087T3 (es) | 1997-06-13 | 2003-07-16 | Genentech Inc | Formulacion estabilizada de un anticuerpo. |
US7833525B2 (en) | 2000-12-28 | 2010-11-16 | Bhami Shenoy | Crystals of whole antibodies and fragments thereof and methods for making and using them |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
AU2002363939A1 (en) | 2001-11-20 | 2003-06-10 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
CA2480059C (en) | 2002-03-22 | 2015-11-24 | Amrad Operations Pty. Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1) |
JP2004016021A (ja) | 2002-06-12 | 2004-01-22 | Japan Science & Technology Corp | 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット |
AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
TWI487535B (zh) * | 2004-11-30 | 2015-06-11 | Centocor Inc | 類鐸受體3(toll like receptor3)拮抗劑,方法及用途 |
EP1945820B1 (en) | 2005-10-27 | 2013-08-28 | Janssen Biotech, Inc. | Toll like receptor 3 modulators, methods and uses |
JP5401639B2 (ja) | 2005-12-08 | 2014-01-29 | メダレックス エル.エル.シー. | タンパク質チロシンキナーゼ7(ptk7)に対するヒトモノクローナル抗体およびそれらの使用 |
US8354508B2 (en) | 2006-07-21 | 2013-01-15 | Diadexus, Inc. | PRO115 antibody compositions and methods of use |
WO2008049897A1 (en) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
EP2155249A4 (en) | 2007-05-15 | 2011-11-16 | Oncomed Pharm Inc | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER |
AU2009239655B2 (en) | 2008-04-25 | 2014-05-22 | Innate Pharma | Improved TLR3 agonist compositions |
US8460659B2 (en) | 2008-10-31 | 2013-06-11 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases |
US20130090457A1 (en) | 2008-10-31 | 2013-04-11 | Janssen Biotech, Inc. | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases |
LT2350304T (lt) | 2008-10-31 | 2017-02-10 | Janssen Biotech, Inc. | Toll tipo receptoriaus 3 antagonistai |
UA112282C2 (uk) | 2009-04-29 | 2016-08-25 | Янссен Байотек, Інк. | Антагоніст толл-подібного рецептора 3 |
CA2766747C (en) | 2009-07-10 | 2019-04-02 | Innate Pharma | Tlr3 binding agents |
ES2438774T3 (es) | 2009-12-11 | 2014-01-20 | Deutsches Krebsforschungszentrum | Anticuerpo que se une a parvovirus H-1 |
US20140065154A1 (en) | 2011-01-12 | 2014-03-06 | Innate Pharma | Tlr3 binding agents |
DK2855527T3 (da) | 2012-05-31 | 2018-11-26 | Innate Pharma | Tlr3-bindemidler |
-
2010
- 2010-07-09 CA CA2766747A patent/CA2766747C/en active Active
- 2010-07-09 JP JP2012519021A patent/JP5800809B2/ja not_active Expired - Fee Related
- 2010-07-09 AU AU2010270163A patent/AU2010270163B2/en not_active Ceased
- 2010-07-09 EP EP10734092.9A patent/EP2451844B1/en active Active
- 2010-07-09 WO PCT/EP2010/059946 patent/WO2011004028A2/en active Application Filing
- 2010-07-09 CN CN2010800309195A patent/CN102471382A/zh active Pending
- 2010-07-09 ES ES10734092.9T patent/ES2543095T3/es active Active
- 2010-07-09 RU RU2012103212/10A patent/RU2562865C2/ru active
- 2010-07-09 DK DK10734092.9T patent/DK2451844T3/da active
-
2011
- 2011-05-05 US US13/102,019 patent/US9388246B2/en not_active Expired - Fee Related
-
2016
- 2016-07-07 US US15/204,851 patent/US20160347853A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2766747A1 (en) | 2011-01-13 |
WO2011004028A2 (en) | 2011-01-13 |
CN102471382A (zh) | 2012-05-23 |
RU2562865C2 (ru) | 2015-09-10 |
US9388246B2 (en) | 2016-07-12 |
CA2766747C (en) | 2019-04-02 |
RU2012103212A (ru) | 2013-08-20 |
EP2451844B1 (en) | 2015-04-22 |
ES2543095T3 (es) | 2015-08-14 |
WO2011004028A9 (en) | 2011-08-11 |
WO2011004028A3 (en) | 2011-05-19 |
AU2010270163A1 (en) | 2012-02-02 |
JP2012532851A (ja) | 2012-12-20 |
EP2451844A2 (en) | 2012-05-16 |
US20120034232A1 (en) | 2012-02-09 |
AU2010270163B2 (en) | 2016-05-05 |
JP5800809B2 (ja) | 2015-10-28 |
US20160347853A1 (en) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2451844T3 (da) | Tlr3-bindingsmidler | |
JP7132981B2 (ja) | Cd73遮断 | |
CN110382536B (zh) | 抗pd-1抗体及其用途 | |
JP7274469B2 (ja) | Cd39/cd73軸によるt細胞活性の回復 | |
KR102022734B1 (ko) | 신규 조절제 및 용법 | |
DK2817338T3 (da) | DLL3-modulatorer og fremgangsmåder til anvendelse | |
AU2011293127B2 (en) | Notum protein modulators and methods of use | |
WO2016131950A1 (en) | Cd73 blockade | |
US20180030144A1 (en) | Cd73 blockade | |
KR20140031175A (ko) | 신규 조절제 및 용법 | |
CA3004972A1 (en) | Siglec-10 antibodies | |
BR112017006464B1 (pt) | Anticorpo isolado, composição farmacêutica, uso de um anticorpo e anticorpo |